Accueil>>Lipids>> Fatty Amides>>Arachidonoyl Cyclopropylamide

Arachidonoyl Cyclopropylamide (Synonyms: ACPA)

Catalog No.GC18615

L'arachidonoyl cyclopropylamide (ACPA) est un agoniste puissant et sélectif du récepteur cannabinoïde (CB) 1 avec des valeurs de Ki de 2,2 et 715 nM pour les récepteurs CB1 et CB2, respectivement.

Products are for research use only. Not for human use. We do not sell to patients.

Arachidonoyl Cyclopropylamide Chemical Structure

Cas No.: 229021-64-1

Taille Prix Stock Qté
5mg
48,00 $US
En stock
10mg
92,00 $US
En stock
50mg
385,00 $US
En stock
100mg
673,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Arachidonoyl cyclopropylamide (ACPA) is a potent and selective cannabinoid (CB) receptor 1 agonist with Ki values of 2.2 and 715 nM for CB1 and CB2 receptors, respectively. In whole animal experiments, ACPA induces hypothermia in mice with the same efficacy as arachidonoyl ethanolamide , in spite of its higher affinity for the CB1 receptor. These data have been interpreted to indicate that ACEA may be a substrate for fatty acid amide hydrolase (FAAH), and thus only transiently available in whole animal experiments.

References:
[1].Pertwee, R.G. Pharmacology of cannabinoid receptor ligands Curr. Med. Chem. 6(8), 635-664 (1999).
[2]. Hillard, C.J., Manna, S., Greenberg, M.J., et al. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1) J. Pharmacol. Exp. Ther. 289(3), 1427-1433 (1999).

Avis

Review for Arachidonoyl Cyclopropylamide

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Arachidonoyl Cyclopropylamide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.